Ilaris Approval History

Ilaris (canakinumab) is a human monoclonal antibody for the treatment of children and adults with cryopyrin-associated periodic syndrome (CAPS), and for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.

FDA Approval History for Ilaris

DateArticle
May 10, 2013Approval Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis
Jun 18, 2009Approval New Biological Therapy Ilaris Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)